STOCK TITAN

Bridgebio Pharma Stock Price, News & Analysis

BBIO Nasdaq

Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.

BridgeBio Pharma (BBIO) is a biopharmaceutical innovator developing genetic disease therapies through its unique portfolio-based approach. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.

Investors and stakeholders gain centralized access to critical updates including clinical milestones, regulatory filings, financial disclosures, and research partnerships. Our curated feed ensures timely tracking of therapeutic advancements across BridgeBio's diversified pipeline.

Key focus areas include progress in Mendelian disorder treatments, oncology targets, and gene therapy innovations. All content undergoes strict verification to maintain compliance with financial disclosure standards and medical accuracy guidelines.

Bookmark this page for efficient monitoring of BBIO's scientific advancements and corporate developments. Combine this resource with SEC filings and earnings transcripts for comprehensive investment analysis.

Rhea-AI Summary

BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the granting of 21,414 restricted stock units to 17 new employees on August 3, 2021. This issuance is part of the company's 2019 Inducement Equity Plan, ensuring compliance with Nasdaq Listing Rule 5635(c)(4). Founded in 2015, BridgeBio focuses on developing innovative treatments for genetic diseases and cancers. The company has over 30 programs in its pipeline, aiming to expedite the delivery of its first approved therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
-
Rhea-AI Summary

BridgeBio Pharma has announced a non-exclusive collaboration with Bristol Myers Squibb to evaluate BBP-398, a promising SHP2 inhibitor, in combination with OPDIVO® for treating advanced solid tumors with KRAS mutations. The collaboration includes a Phase 1/2 trial assessing the safety and efficacy of BBP-398 alongside OPDIVO as doublet therapy and with a KRASG12C inhibitor as triplet therapy in non-small cell lung cancer. Both companies will co-fund the clinical development activities. BRIDGE Bio aims to provide new treatment options for patients with difficult-to-treat cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.56%
Tags
none
-
Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced on July 1, 2021, that its compensation committee granted 20 new employees restricted stock units totaling 26,761 shares. This was done as an inducement for new hires, in compliance with Nasdaq Listing Rule 5635(c)(4). These awards were made under BridgeBio's 2019 Inducement Equity Plan, which aims to attract talent in the biopharmaceutical sector to develop treatments for genetic diseases and cancers. The company has over 30 ongoing development programs focused on advancing its first approved therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced collaborations with three academic institutions: MUSC Foundation for Research Development, Stanford University, and the University of Pittsburgh. These partnerships aim to translate innovative research into therapies for genetic diseases and cancers. BridgeBio's CEO, Neil Kumar, emphasized the significance of these collaborations in accelerating the development of life-changing medicines. The company has previously partnered with 23 institutions, showcasing its commitment to advancing patient treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
-
Rhea-AI Summary

On June 1, 2021, BridgeBio Pharma (Nasdaq: BBIO) granted restricted stock units totaling 47,963 shares to 21 new employees under the 2019 Inducement Equity Plan. This action is compliant with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new hires. BridgeBio is dedicated to developing medicines for genetic diseases and cancers, with over 30 programs in its pipeline. Founded in 2015, the company focuses on rapid advancements in genetic medicine to benefit patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
none
-
Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced that the FDA granted Fast Track designation to encaleret for treating autosomal dominant hypocalcemia (ADH1). This rare genetic condition affects approximately 12,000 people in the U.S., causing severe calcium regulation issues. Current treatments are insufficient. Promising early results from a Phase 2b study show 100% normalization of blood and urine calcium in participants. This designation may expedite development and approval of encaleret, potentially the first therapy specifically for ADH1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
Rhea-AI Summary

BridgeBio Pharma and Helsinn announced the FDA's approval of TRUSELTIQ (infigratinib) for previously-treated patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion. This marked BridgeBio's first oncology product approved by the FDA and the second overall this year. In clinical trials, TRUSELTIQ demonstrated a objective response rate of 23% and a median duration of response of 5 months. The companies will co-commercialize TRUSELTIQ in the U.S., sharing profits and losses equally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
-
Rhea-AI Summary

On May 4, 2021, BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the granting of restricted stock units for 70,949 shares to 27 new employees. This decision was made by the compensation committee under the company's 2019 Inducement Equity Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The Plan aims to incentivize new hires effectively. Founded in 2015, BridgeBio focuses on developing medicines for genetic diseases and cancers, with over 30 programs in various clinical stages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced FDA Fast Track designation for BBP-631, a gene therapy for congenital adrenal hyperplasia (CAH). This designation aims to expedite the development of treatments addressing significant unmet medical needs. CAH affects over 75,000 cases in the U.S. and Europe. The company also presented preclinical data supporting the safety and efficacy of BBP-631 at the ASGCT Annual Meeting. Initial clinical trials are anticipated to begin soon, with data expected in late 2021 or early 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
none
Rhea-AI Summary

BridgeBio Pharma has achieved significant milestones, including FDA approval for NULIBRY™ (fosdenopterin) as the first treatment for molybdenum cofactor deficiency Type A. The company reported proof-of-concept data for encaleret in Autosomal Dominant Hypocalcemia Type 1. A collaboration with Helsinn Group aims to co-develop infigratinib in oncology, with potential earnings of up to $2.45 billion. The completion of Eidos Therapeutics acquisition and the issuance of $750 million in Convertible Senior Notes bolster financial stability, ending Q1 2021 with $1 billion in cash and securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags

FAQ

What is the current stock price of Bridgebio Pharma (BBIO)?

The current stock price of Bridgebio Pharma (BBIO) is $34.17 as of May 9, 2025.

What is the market cap of Bridgebio Pharma (BBIO)?

The market cap of Bridgebio Pharma (BBIO) is approximately 7.3B.
Bridgebio Pharma

Nasdaq:BBIO

BBIO Rankings

BBIO Stock Data

7.32B
157.42M
5.41%
91.1%
11.65%
Biotechnology
Pharmaceutical Preparations
Link
United States
PALO ALTO